Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2016

Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2016
Published Nov 23, 2016
191 pages — Published Nov 23, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H5N1 Subtype Infections Pipeline Review, H2 2016, provides an overview of the Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline landscape.

H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called avian influenza. This virus can spread to humans. Symptoms include fever and cough, acute respiratory distress, shortness of breath/difficulty breathing, abdominal pain and diarrhea. Predisposing factors include work with poultry, touch an infected bird and eating raw or undercooked poultry meat. Treatment includes antiviral medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H5N1 Subtype Infections Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H5N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 6, 14, 1, 30 and 7 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively.Influenza A Virus, H5N1 Subtype Infections.

Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics and enlists all thei

  
Source:
Document ID
GMDHC8695IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents211
  List of Tables111
  List of Figures121
Introduction131
  Global Markets Direct Report Coverage131
Influenza A Virus, H5N1 Subtype Infections Overview141
Therapeutics Development152
  Pipeline Products for Influenza A Virus, H5N1 Subtype Infections Overview151
  Pipeline Products for Influenza A Virus, H5N1 Subtype Infections Comparative Analysis161
Influenza A Virus, H5N1 Subtype Infections Therapeutics under Development by Companies173
Influenza A Virus, H5N1 Subtype Infections Therapeutics under Investigation by Universities/Institutes201
Influenza A Virus, H5N1 Subtype Infections Pipeline Products Glance213
  Late Stage Products211
  Clinical Stage Products221
  Early Stage Products231
Influenza A Virus, H5N1 Subtype Infections Products under Development by Companies244
Influenza A Virus, H5N1 Subtype Infections Products under Investigation by Universities/Institutes281
Influenza A Virus, H5N1 Subtype Infections Companies Involved in Therapeutics Development2936
  Akshaya Bio Inc291
  Altimmune Inc301
  Antigen Express Inc311
  Aphios Corp321
  BioDiem Ltd331
  BiondVax Pharmaceuticals Ltd341
  CEL-SCI Corp351
  Cocrystal Pharma Inc361
  Emergent BioSolutions Inc371
  Gemmus Pharma Inc381
  GlaxoSmithKline Plc391
  Hemispherx Biopharma Inc401
  iBio Inc411
  Inovio Pharmaceuticals Inc421
  Johnson &Johnson431
  Kineta Inc441
  Lakewood-Amedex Inc451
  Medicago Inc461
  Medigen Vaccine Biologics Corp.471
  Microbiotix Inc481
  NanoBio Corp491
  Nanotherapeutics Inc501
  NanoViricides Inc511
  NewLink Genetics Corp521
  OPKO Health Inc531
  PaxVax Inc541
  PeptiDream Inc551
  Protein Sciences Corp561
  Shionogi &Co Ltd571
  Takeda Pharmaceutical Company Ltd581
  TechnoVax Inc591
  TGV-Laboratories601
  Vaxart Inc611
  Vaxine Pty Ltd621
  VaxInnate Corp631
  Visterra Inc641
Influenza A Virus, H5N1 Subtype Infections Therapeutics Assessment6510
  Assessment by Monotherapy Products651
  Assessment by Combination Products661
  Assessment by Target672
  Assessment by Mechanism of Action692
  Assessment by Route of Administration712
  Assessment by Molecule Type732
Drug Profiles7598
  A-06 Drug Profile751
  AE-443p Drug Profile761
  Alferon LDO Drug Profile772
  APP-0205 Drug Profile791
  APP-309 Drug Profile801
  AT-301 Drug Profile811
  CEL-1000 Drug Profile822
  CHOS-05 Drug Profile841
  DPC-005 Drug Profile851
  FBF-001 Drug Profile861
  Gamma-Flu Drug Profile871
  GP-1001 Drug Profile881
  GP-1002 Drug Profile891
  GP-1681 Drug Profile902
  GREFLU/VIE Drug Profile921
  HAI-05 Drug Profile931
  HB-36.6 Drug Profile941
  Influ-nRNA Drug Profile951
  influenza [strain A/H5N1] (split virion) vaccine Drug Profile961
  influenza [strain A/H5N1] (virus like particle) vaccine 2 Drug Profile973
  influenza [strain A/H5N1] vaccine Drug Profile1001
  influenza [strain A/H5N1] vaccine Drug Profile1011
  influenza [strain A/H5N1] vaccine Drug Profile1022
  influenza [strain A/H5N1] vaccine Drug Profile1041
  influenza [strain A/H5N1] vaccine Drug Profile1051
  influenza [strain A/H5N1] vaccine Drug Profile1061
  influenza [strain A/H5N1] vaccine Drug Profile1071
  influenza [strain A/H5N1] vaccine Drug Profile1081
  influenza [strain A/H5N1] vaccine Drug Profile1091
  influenza [strain A/H5N1] vaccine 2 Drug Profile1101
  influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine Drug Profile1111
  influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine Drug Profile1121
  influenza [strains A/H5N1 + A/H1N1] vaccine Drug Profile1131
  influenza [strains A/H5N1 + A/H7N2 + A/H9N2] (virus like particle) vaccine Drug Profile1141
  influenza vaccine Drug Profile1151
  INO-3510 Drug Profile1162
  JNJ-872 Drug Profile1182
  KD-295 Drug Profile1201
  KIN-1148 Drug Profile1211
  Lalistat Drug Profile1221
  M-001 Drug Profile1235
  MBX-2329 Drug Profile1281
  MBX-2546 Drug Profile1291
  Monoclonal Antibodies to Inhibit Hemagglutinin for Avian Infection and Swine Flu Infection Drug Profile1301
  MV-4 Drug Profile1311
  MVAH-5HA Drug Profile1321
  Nasovax Drug Profile1332
  NVINF-1 Drug Profile1354
  NVINF-2 Drug Profile1393
  OrniFlu Drug Profile1421
  PanBlok Drug Profile1433
  PD-001 Drug Profile1461
  PNSIA-28 Drug Profile1471
  PNSIA-49 Drug Profile1481
  PXVX-0103 Drug Profile1491
  rintatolimod Drug Profile1509
  S-033188 Drug Profile1592
  Small Molecules for Influenza A Virus H1N1 and H5N1 Infections Drug Profile1611
  Small Molecules to Activate Sirtuin for Influenza Drug Profile1621
  Small Molecules to Inhibit PB2 for Influenza Drug Profile1631
  Synthetic Peptides for Influenza, HSV and HIV Infections Drug Profile1641
  Synthetic Peptides for Viral Infections Drug Profile1651
  TVX-003 Drug Profile1661
  VAX-161C Drug Profile1671
  VGX-3400X Drug Profile1681
  VH-244 Drug Profile1691
  VIS-410 Drug Profile1703
Influenza A Virus, H5N1 Subtype Infections Dormant Projects1736
Influenza A Virus, H5N1 Subtype Infections Discontinued Products1791
Influenza A Virus, H5N1 Subtype Infections Product Development Milestones18010
  Featured News &Press Releases1801
    Jun 01, 2016: NanoBio To Present Data Demonstrating Benefit Of Its Intramuscular Nanoemulsion Pandemic Influenza Vaccine1801
    Mar 22, 2016: Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress1811
    Sep 30, 2015: BiondVax Initiates a Phase IIb Clinical Trial in Europe for its Universal Flu Vaccine for Pandemic Outbreak1811
    Jun 02, 2015: Visterra Announces Presentation of Data at International Influenza Meeting on the Efficacy of VIS410 for Treatment of a Deadly Strain of Avian Influenza1821
    Mar 23, 2015: Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress in Washington D.C.1821
    Oct 29, 2014: BiondVax Receives Approvals for Patent in Europe and Japan for its Universal Flu Vaccine1831
    Mar 24, 2014: Valneva Announces the First Ever Marketing Authorization for a Human Vaccine Produced in the EB66 Cell Line1831
    Feb 17, 2014: BiondVax will Present Clinical Results and the Company's Strategy for Pandemic Preparedness Ahead of Flu Outbreak at the World Health Organization's Key Influenza Meeting1841
    Feb 10, 2014: BiondVax Receives Patent Registration Approval for Multimeric Multiepitope Influenza Vaccines in Hong Kong as well as Allowance of Patent Registration in US for the Company s Universal Flu Vaccine1841
    Jan 21, 2014: BiondVax s universal flu vaccine matches all 6 potentially pandemic flu strains in the world today: H5N1, H5N8, H6N1, H7N 7 , H7N 9 and H10N81851
    Oct 03, 2013: BiondVax is a member of the UNISEC consortium awarded a European Commission FP7 grant of 6 million EURO1861
    Sep 09, 2013: Visterra Presents Prophylactic and Therapeutic Efficacy Data of VIS410 Against Multiple Influenza Strains with Pandemic Potential1861
    Aug 25, 2013: Priming with BiondVax s universal influenza vaccine broadens the activity of conventional bird pandemic vaccine against emerging strains1871
    Apr 09, 2013: Medicago And IDRI To Present Positive Interim Phase I Clinical Trial Results Of H5N1 Vaccine At 2013 World Vaccine Congress1881
    Apr 02, 2013: Vivalis Announces Submission Of First New Drug Application For H5N1 Pandemic Influenza Vaccine In Japan1891
Appendix1902
  Methodology1901
  Coverage1901
  Secondary Research1901
  Primary Research1901
  Expert Panel Validation1901
  Contact Us1901
  Disclaimer1911

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2016" Nov 23, 2016. Alacra Store. Mar 29, 2024. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Influenza-A-Virus-H5N1-Subtype-Infections-Pipeline-Review-H2-2016-2088-16870>
  
APA:
Global Markets Direct - Market Research. (2016). Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2016 Nov 23, 2016. New York, NY: Alacra Store. Retrieved Mar 29, 2024 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Influenza-A-Virus-H5N1-Subtype-Infections-Pipeline-Review-H2-2016-2088-16870>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.